Skip to main content

Table 3 ROC Curve to Confirm Cyclin D1 Immunostaining Cutoff Threshold

From: Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules

Histology
 Immunolabelling cells Percentage of Cyclin D1 immunolabelled tumor cells
Cut off (%) AUC p Sensitivity (%) Specificity (%)
 Carcinoma VS Adenoma/Background 15.7 0.89 <.0001* 86.4 80.5
 Carcinoma/Adenoma VS Background 5.8 0.93 0.003* 94.4 92.3
 Immunolabelling cells Percentage of Ki67 immunolabelled tumor cells
Cut off (%) AUC p Sensitivity (%) Specificity (%)
 Carcinoma VS Adenoma/Background 3.5 0.58 NS 53.1 71.4
 Carcinoma/Adenoma VS Background 5 0.54 NS 33.7 92.3
Cytology
 Immunolabelling cells Percentage of Cyclin D1 immunolabelled tumor cells
Cut off (%) AUC p Sensitivity (%) Specificity (%)
 Malignant VS Adenoma/Background 46 0.96 <.0001* 85 100